Ad26.cov2-s/elasomeranLack of efficacy:2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1942卷 / 1期

关键词：

D O I：

10.1007/s40278-023-32626-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：17 / 17

相关论文

共 50 条

[41] Ad26.cov2-s/methylprednisoloneAntineutrophil cytoplasmic autoantibodies associated glomerulonephritis and lack of efficacy: case report
Reactions Weekly, 2022, 1923 (1) : 20 - 20
[42] Ad26.COV2-S/omalizumabIdiopathic bradykinin-mediated angioedema and lack of efficacy: case report
Reactions Weekly, 2023, 1943 (1) : 19 - 19
[43] Ad26.COV2-S/AZD-1222/tozinameranGuillain-Barre syndrome: 4 case reports
Reactions Weekly, 2023, 1947 (1) : 20 - 20
[44] Ad26.cov2-s/elasomeran/tozinameranSensorineural Hearing Loss: case report
Reactions Weekly, 2022, 1906 (1) : 20 - 20
[45] Ad26.cov2-s/elasomeran/tozinameranBell's palsy and Guillain-Barre syndrome: 4 case reports
Reactions Weekly, 2023, 1966 (1) : 16 - 16
[46] Ad26.cov2-s/tozinameranMinimal change disease and podocytopathic focal segmental glomerulosclerosis: 3 case reports
Reactions Weekly, 2022, 1905 (1) : 17 - 17
[47] Ad26.COV2-S/AZD-1222Vaccine-induced thrombotic thrombocytopenia: 13 case reports
Reactions Weekly, 2022, 1916 (1) : 18 - 18
[48] Ad26.COV2-S/RituximabProtracted COVID 19, plasma cell depletion and lack of efficacy : case report
Reactions Weekly, 2022, 1917 (1) : 24 - 24
[49] Ad26.COV2-S/TozinameranDe novo immune thrombocytopenia
Reactions Weekly, 2024, 2002 (1) : 17 - 17
[50] Ad26.COV2-S/elasomeran/tozinameranVulval aphthous ulcers
Reactions Weekly, 2024, 2000 (1) : 16 - 16

← 1 2 3 4 5 →